DOCSLIB.ORG

Chapter 129: Paraneoplastic Syndromes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Chapter 129: Paraneoplastic Syndromes CHAPTER 129 – REFERENCES 1. Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis 33. Kalia J, Swartz KJ. Elucidating the molecular basis of action of a classic drug: and treatment. Mayo Clin Proc 2010;85:838–854. guanidine compounds as inhibitors of voltage-gated potassium channels. 2. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous sys- Mol Pharmacol 2011;80:1085–1095. tem. N Engl J Med 2003;349:1543–1554. 34. Sanders DB, Massey JM, Sanders LL, et al. A randomized trial of 3. Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J 3,4- diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology Rare Dis 2007;2:22. 2000;54:603–607. 4. de Beukelaar JW, Sillevis Smitt PA. Managing paraneoplastic neurological 35. McEvoy KM, Windebank AJ, Daube JR, et al. 3,4-Diaminopyridine in the disorders. Oncologist 2006;11:292–305. treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 1989;321: 5. Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies 1567–1571. to synaptic and neuronal cell surface proteins. Neurology 2011;77:179–189. 36. Low PA. Autonomic neuropathies. Curr Opin Neurol 2002;15:605–609. 6. Albert ML, Austin LM, Darnell RB. Detection and treatment of activated 37. Gupta V, Lipsitz LA. Orthostatic hypotension in the elderly: diagnosis and T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar treatment. Am J Med 2007;120:841–847. degeneration. Ann Neurol 2000;47:9–17. 38. Calvet X, Martinez JM, Martinez M. Repeated neostigmine dosage as pal- 7. Antoine JC, Camdessanche JP. Treatment options in paraneoplastic dis- liative treatment for chronic colonic pseudo-obstruction in a patient with orders of the peripheral nervous system. Curr Treat Options Neurol 2013; autonomic paraneoplastic neuropathy. Am J Gastroenterol 2003;98:708–709. 15:210–223. 39. Graus F, Dalmou J, Rene R, et al. Anti-Hu antibodies in patients with small- 8. Psimaras D, Carpentier AF, Rossi C, et al. Cerebrospinal fluid study in para- cell lung cancer: association with complete response to therapy and im- neoplastic syndromes. J Neurol Neurosurg Psychiatry 2010;81:42–45. proved survival. J Clin Oncol 1997;15:2866–2872. 9. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria 40. Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2006;69:2124–2130. 2004;75:1135–1140. 41. Lehrich RW, Ortiz-Melo DI, Patel MB, et al. Role of vaptans in the manage- 10. Kannoth S. Paraneoplastic neurologic syndrome: A practical approach. Ann ment of hyponatremia. Am J Kidney Dis 2013;62:364–376. Indian Acad Neurol 2012;15:6–12. 42. Raftopoulos H. Diagnosis and management of hyponatremia in cancer pa- 11. Wright CE, Angus JA. Effects of N-, P- and Q-type neuronal calcium chan- tients. Support Care Cancer 2007;15:1341–1347. nel antagonists on mammalian peripheral neurotransmission. Br J Pharmacol 43. List AF, Hainsworth JD, Davis BW, et al. The syndrome of inappropriate 1996;119:49–56. secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. J Clin 12. Perez-Reyes E. Molecular physiology of low-voltage-activated t-type calcium Oncol 1986;4:1191–1198. channels. Physiol Rev 2003;83:117–161. 44. Talmi YP, Hoffman HT, McCabe BF. Syndrome of inappropriate secretion 13. Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in of arginine vasopressin in patients with cancer of the head and neck. Ann the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Otol Rhinol Laryngol 1992;101:946–949. Med 1995;332:1467–1474. 45. Ferlito A, Rinaldo A, Devaney KO. Syndrome of inappropriate antidiuretic 14. Bernal F, Shams’ili S, Rojas I, et al. Anti-Tr antibodies as markers of paraneo- hormone secretion associated with head neck cancers: review of the litera- plastic cerebellar degeneration and Hodgkin’s disease. Neurology 2003;60: ture. Ann Otol Rhinol Laryngol 1997;106:878–883. 230–234. 46. Lee BW, Ihm SH, Shin HS, et al. Malignant thymoma associated with myas- 15. Linke R, Schroeder M, Helmberger T, et al. Antibody-positive paraneoplastic thenia gravis, Graves’ disease, and SIADH. Intern Med 2008;47:1009–1012. neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology 47. Galesic K, Krizanac S, Vrkljan M, et al. Syndrome of inappropriate secre- 2004;63:282–286. tion of antidiuretic hormone due to malignant thymoma. Nephron 2002;91: 16. Shams’ili S, Grefkens J, de Leeuw B, et al. Paraneoplastic cerebellar degen- 752–754. eration associated with antineuronal antibodies: analysis of 50 patients. Brain 48. Eliakim R, Vertman E, Shinhar E. Syndrome of inappropriate secretion of 2003;126:1409–1418. antidiuretic hormone in Hodgkin’s disease. Am J Med Sci 1986;291:126–127. 17. Mason WP, Graus F, Lang B, et al. Small-cell lung cancer, paraneoplastic 49. Kobayashi K, Yokote T, Akioka T, et al. Inappropriate antidiuretic hormone cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain production in diffuse large B-cell lymphoma. Br J Haematol 2008;143:2. 1997;120:1279–1300. 50. Hirata Y, Yokote T, Nishiwaki U, et al. Syndrome of inappropriate antidi- 18. Bataller L, Graus F, Saiz A, et al. Clinical outcome in adult onset idiopathic uretic hormone secretion associated with primary cutaneous anaplastic large or paraneoplastic opsoclonus-myoclonus. Brain 2001;124:437–443. cell lymphoma. Br J Haematol 2012;157:412. 19. Hassan KA, Kalemkerian GP, Trobe JD. Long-term survival in paraneoplas- 51. Nagashima Y, Iino K, Oki Y, et al. A rare case of ectopic antidiuretic hor- tic opsoclonus-myoclonus syndrome associated with small cell lung cancer. mone-producing pancreatic adenocarcinoma: new diagnostic approach. In- J Neuroophthalmol 2008;28:27–30. tern Med 1996;35:280–284. 20. DiBaise JK. Paraneoplastic gastrointestinal dysmotility: when to consider and 52. Garzotto M, Beer TM. Syndrome of inappropriate antidiuretic hormone se- how to diagnose. Gastroenterol Clin North Am 2011;40:777–786. cretion: a rare complication of prostate cancer. J Urol 2001;166:1386. 21. Lennon VA, Sas DF, Busk MF, et al. Enteric neuronal autoantibodies in pseu- 53. Yamazaki T, Suzuki H, Tobe T, et al. Prostate adenocarcinoma producing doobstruction with small-cell lung carcinoma. Gastroenterology 1991;100: syndrome of inappropriate secretion of antidiuretic hormone. Int J Urol 137–142. 2001;8:513–516. 22. Lee HR, Lennon VA, Camilleri M, et al. Paraneoplastic gastrointestinal mo- 54. Gasparini ME, Broderick GA, Narayan P. The syndrome of inappropriate tor dysfunction: clinical and laboratory characteristics. Am J Gastroenterol antidiuretic hormone secretion in a patient with adenocarcinoma of the pros- 2001;96:373–379. tate. J Urol 1993;150:978–980. 23. Zisimopoulou P, Brenner T, Trakas N, et al. Serological diagnostics in myas- 55. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med 2000;342: thenia gravis based on novel assays and recently identified antigens.Autoim- 1581–1589. mun Rev 2013;12:924–930. 56. Arieff AI, Llach F, Massry SG. Neurological manifestations and morbidity 24. Evoli A, Minisci C, Di Schino C, et al. Thymoma in patients with MG: of hyponatremia: correlation with brain water and electrolytes. Medicine characteristics and long-term outcome. Neurology 2002;59:1844–1850. 1976;55:121–129. 25. Rosenberg M, Jauregui WO, De Vega ME, et al. Recurrence of thymic hy- 57. Gross P, Reimann D, Neidel J, et al. The treatment of severe hyponatremia. perplasia after thymectomy in myasthenia gravis. Its importance as a cause of Kidney Int Suppl 1998;64:S6–S11. failure of surgical treatment. Am J Med 1983;74:78–82. 58. Gullans SR, Verbalis JG. Control of brain volume during hyperosmolar and 26. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic hypoosmolar conditions. Ann Rev Med 1993;44:289–301. factors for long-term outcome in patients with anti-NMDA receptor enceph- 59. Renneboog B, Musch W, Vandemergel X, et al. Mild chronic hyponatre- alitis: an observational cohort study. Lancet Neurol 2013;12:157–165. mia is associated with falls, unsteadiness, and attention deficits.Am J Med 27. Wirtz PW, Sotodeh M, Nijnuis M, et al. Difference in distribution of muscle 2006;119:71.e1–e8. weakness between myasthenia gravis and the Lambert-Eaton myasthenic syn- 60. Schwartz WB, Bennett W, Curelop S, et al. A syndrome of renal sodium loss drome. J Neurol Neurosurg Psychiatry 2002;73:766–768. and hyponatremia probably resulting from inappropriate secretion of antidi- 28. Oh SJ, Kurokawa K, Claussen GC, et al. Electrophysiological diagnostic crite- uretic hormone. Am J Med 1957;23:529–542. ria of Lambert-Eaton myasthenic syndrome. Muscle Nerve 2005;32:515–520. 61. Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of an- 29. Voltz R. Intravenous immunoglobulin therapy in paraneoplastic neurologi- tidiuretic hormone. Am J Med 1967;42:790–806. cal syndromes. J Neurol 2006;253:V33–V38. 62. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidi- 30. Pranzatelli MR, Tate ED, Travelstead AL, et al. Rituximab (anti-CD20) uresis. N Engl J Med 2007;356:2064–2072. adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol 63. Feldman BJ, Rosenthal SM, Vargas GA, et al. Nephrogenic syndrome of in- Oncol 2006;28:585–593. appropriate antidiuresis. N Engl J Med 2005;352:1884–1890. 31. Shams’ili S, de Beukelaar J, Gratama JW, et al. An uncontrolled trial of ritux- 64. Decaux G, Brimioulle S, Genette F, et al. Treatment of the syndrome of imab for antibody associated paraneoplastic neurological syndromes. J Neu- inappropriate secretion of antidiuretic hormone by urea. Am J Med 1980;69: rol 2006;253:16–20. 99–106. 32. Punga AR, Stalberg E.
Load more

Recommended publications
  • 82858686.Pdf
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Frontiers - Publisher Connector MINI REVIEW published: 23 March 2017 doi: 10.3389/fimmu.2017.00336 Adaptive Immunity Is the Key to the Understanding of Autoimmune and Paraneoplastic inflammatory Central Nervous System Disorders Robert Weissert* Department of Neurology, Neuroimmunology, University of Regensburg, Regensburg, Germany There are common aspects and mechanisms between different types of autoimmune diseases such as multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSDs), and autoimmune encephalitis (AE) as well as paraneoplastic inflammatory disorders of the central nervous system. To our present knowledge, depending on the disease, T and B cells as well as antibodies contribute to various aspects of the pathogenesis. Possibly the events leading to the breaking of tolerance between the different diseases are of great similarity and so far, only partially understood. Beside Edited by: endogenous factors (genetics, genomics, epigenetics, malignancy) also exogenous fac- Björn Tackenberg, tors (vitamin D, sun light exposure, smoking, gut microbiome, viral infections) contribute Philipps University of Marburg, Germany to susceptibility in such diseases. What differs between these disorders are the target Reviewed by: molecules of the immune attack. For T cells, these target molecules are presented on Anne Kathrin Mausberg, major histocompatibility complex (MHC) molecules as MHC-bound ligands. B cells have Essen University Hospital, Germany Pavan Bhargava, an important role by amplifying the immune response of T cells by capturing antigen with Johns Hopkins School of Medicine, their surface immunoglobulin and presenting it to T cells. Antibodies secreted by plasma USA cells that have differentiated from B cells are highly structure specific and can have *Correspondence: important effector functions leading to functional impairment or/and lesion evolvement.
    [Show full text]
  • 214622Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 214622Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review NDA214622 Multi‐disciplinary Review and Evaluation Infigratinib (Truseltiq) NDA/BLA Multi‐disciplinary Review and Evaluation FDA review was conducted in conjunction with other regulatory authorities under a regular ORBIS. While the application review is completed by the FDA, the application is still under review at the other regulatory agencies (Health Canada and Therapeutic Goods Administration). Disclaimer: In this document, the sections labeled as “Data” and “The Applicant’s Position” are completed by the Applicant, which do not necessarily reflect the positions of the FDA. Application Type NDA Application Number(s) 214622 Priority or Standard Priority Submit Date(s) September 29, 2020 Received Date(s) September 29, 2020 PDUFA Goal Date May 29, 2021 Division/Office OOD/DO3 Review Completion Date Please check electronic date stamp Established Name Infigratinib Trade Name Truseltiq Pharmacologic Class FGFR Inhibitor Code name BGJ398 Applicant QED Therapeutics, Inc. Formulation(s) Oral capsule Dosing Regimen 125 mg orally once daily for 21 consecutive days followed by 7 days off therapy, in 28‐day cycles Applicant Proposed The treatment of adult patients with previously treated, Indication(s)/Population(s) unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or other rearrangement as detected by an FDA approved test. Recommendation on Approval Regulatory Action Recommended For the treatment of adults with previously treated, Indication(s)/Population(s) unresectable locally advanced or metastatic (if applicable) cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA‐approved test.
    [Show full text]
  • Read PDF Edition
    REVIEW OF OPTOMETRY EARN 2 CE CREDITS: Positive Visual Phenomena—Etiologies Beyond the Eye, PAGE 58 ■ VOL. 155 NO. 1 January 15, 2018 www.reviewofoptometry.comwww.reviewofoptometry.com ■ ANNUAL CORNEA REPORT JANUARY 15, 2018 ■ CXL ■ EPITHELIAL DEFECTS How to Heal Persistent Epithelial Defects PAGE 38 ■ TRANSPLANTS Corneal Transplants: The OD’s Role PAGE 44 ■ INFILTRATES Diagnosing Corneal Infiltrative Disease PAGE 50 ■ POSITIVE VISUAL PHENOMENA CXL: Your Top 12 Questions —Answered! PAGE 30 001_ro0118_fc.indd 1 1/5/18 4:34 PM ĊčĞĉėĆęĊĉĆĒēĎĔęĎĈĒĊĒćėĆēĊċĔėĎēǦĔċċĎĈĊĕėĔĈĊĉĚėĊĘ ĊđĎĊċĎēĘĎČčę ċċĊĈęĎěĊ Ȉ 1 Ȉ 1 ĊđđǦęĔđĊėĆęĊĉ Ȉ Ȉ ĎĒĕđĊĎēǦĔċċĎĈĊĕėĔĈĊĉĚėĊ Ȉ Ȉ ĔēěĊēĎĊēę Ȉ͝ Ȉ Ȉ Ƭ 1 ǡ ǡǡǤ͚͙͘͜Ǥ Ȁ Ǥ ͚͙͘͜ǣ͘͘ǣ͘͘͘Ǧ͘͘͘ ĕĕđĎĈĆęĎĔēĘ Ȉ Ȉ Ȉ Ȉ Ȉ čĊĚėĎĔē̾ėĔĈĊĘĘ Ȉ Ȉ Katena — Your completecomplete resource forfor amniotic membrane pprocedurerocedure pproducts:roducts: Single use speculums Single use spears ͙͘͘ǡ͘͘͘ήĊĞĊĘęėĊĆęĊĉ Forceps ® ,#"EWB3FW XXXLBUFOBDPNr RO0118_Katena.indd 1 1/2/18 10:34 AM News Review VOL. 155 NO. 1 ■ JANUARY 15, 2018 IN THE NEWS Accelerated CXL Shows The FDA recently approved Luxturna (voretigene neparvovec-rzyl, Spark Promise—and Caution Therapeutics), a directly administered gene therapy that targets biallelic This new technology is already advancing, but not without RPE65 mutation-associated retinal dystrophy. The therapy is designed to some bumps in the road. deliver a normal copy of the gene to By Rebecca Hepp, Managing Editor retinal cells to restore vision loss. While the approval provides hope for patients, wo new studies highlight the resulted in infection—while tradi- the $425,000 per eye price tag stands as pros and cons of accelerated tional C-CXL has a reported inci- a signifi cant hurdle.
    [Show full text]
  • Neuro-Ophthalmic Side Effects of Molecularly Targeted Cancer Drugs
    Eye (2018) 32, 287–301 © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 0950-222X/18 www.nature.com/eye 1,2,3 4 Neuro-ophthalmic side MT Bhatti and AKS Salama REVIEW effects of molecularly targeted cancer drugs Abstract The past two decades has been an amazing time culminated in indescribable violence and in the advancement of cancer treatment. Mole- unspeakable death. However, amazingly within cularly targeted therapy is a concept in which the confines of war have risen some of the specific cellular molecules (overexpressed, greatest advancements in medicine. It is within mutationally activated, or selectively expressed this setting—in particular World War II with the proteins) are manipulated in an advantageous study of mustard gas—that the annals of cancer manner to decrease the transformation, prolif- chemotherapy began touching the lives of eration, and/or survival of cancer cells. In millions of people. It is estimated that in 2016, addition, increased knowledge of the role of the over 1.6 million people in the United States will immune system in carcinogenesis has led to the be diagnosed with cancer and over a half a development of immune checkpoint inhibitors million will die.1 The amount of money being to restore and enhance cellular-mediated anti- spent on research and development of new tumor immunity. The United States Food and cancer therapies is staggering with a record $43 Drug Administration approval of the chimeric billion dollars spent in 2014. Nearly 30% of all monoclonal antibody (mAb) rituximab in 1997 registered clinical trials on the clinicaltrials.gov 1Department of for the treatment of B cell non-Hodgkin lym- website pertain to cancer drugs.
    [Show full text]
  • Rituximab Monotherapy and Rituximab-Containing
    J Clin Exp Hematop Vol. 55, No. 2, Nov. 2015 Case Study Rituximab Monotherapy and Rituximab-Containing Chemotherapy Were Effective for Paraneoplastic Pemphigus Accompanying Follicular Lymphoma, but not for Subsequent Bronchiolitis Obliterans Taichi Hirano,1) Yusuke Higuchi,1) Hiromichi Yuki,1) Shinya Hirata,1) Kisato Nosaka,1) Norito Ishii,2) Takashi Hashimoto,2) Hiroaki Mitsuya,1) and Yutaka Okuno1) A 60-year-old male patient suffered from mild exertional dyspnea, wheezing, and systemic blisters. He was diagnosed with paraneoplastic pemphigus (PNP) with follicular lymphoma in the pancreas head and pelvic cavity. He was first treated with eight cycles of rituximab; his blisters and erosions gradually improved and highly elevated levels of auto-antibodies related to PNP gradually decreased to normal levels. However, obstructive and restrictive respiratory failure still progressed. Computed tomography of the inspiratory and expiratory phases revealed obstructive pulmonary disorder, leading to a diagnosis of bronchiolitis obliterans (BO). The patient underwent plasma exchange and was repeatedly treated with rituximab monotherapy and rituximab-containing chemotherapies, but died 7 months after the diagnosis of BO. Early introduction of rituximab- containing regimens may be necessary to prevent the development of BO accompanying PNP. However, when a diagnosis of PNP-related BO is made, lung transplantation may also be considered for patients in whom rituximab-containing regimens are effective for PNP. 〔J Clin Exp Hematop 55(2) : 83-88, 2015〕 Keywords: follicular lymphoma, paraneoplastic pemphigus, bronchiolitis obliterans, rituximab Without control of the malignant neoplasms, resolution of the INTRODUCTION skin blisters is difficult and requires high doses of cortico- Paraneoplastic pemphigus (PNP) is a systemic autoim- steroids and immunosuppressive drugs.
    [Show full text]
  • Eyelash-Enhancing Products: a Review Bishr Al Dabagh, MD; Julie Woodward, MD
    Review Eyelash-Enhancing Products: A Review Bishr Al Dabagh, MD; Julie Woodward, MD Long prominent eyelashes draw attention to the eyes and are considered a sign of beauty. Women strive to achieve ideal lashes through various modalities, including cosmetics, cosmeceuticals, and pharmaceu- ticals. The booming beauty industry has introduced many cosmetic and cosmeceutical products with claims of enhancing eyelash growth; however, many of these products have not been tested for efficacy or safety and are promoted solely with company- and/or consumer-based claims. The only pharmaceu- tical approved by the US Food and Drug Administration for eyelash growth is bimatoprost ophthalmic solution 0.03% (Latisse, Allergan, Inc). In this article, eyelash physiology, causes of genetic and acquired trichomegaly, and pharmaceutical and cosmeceutical products that claim eyelash-enhancing effects are reviewed. COS DERMCosmet Dermatol. 2012;25:134-143. yelashes decorate the eyes and crystallize cosmeceuticals contain active ingredients that are intended the beauty of the face.1 Long and lush eye- to produce beneficial physiologic effects through medicinal Dolashes in particular Notare considered a sign properties. Copy3,4 Cosmeceuticals fall in the gray area between of beauty. Women strive to achieve more inert cosmetics and pharmaceuticals. Drugs are defined pronounced eyelashes using a variety of tech- by the FDA as “articles intended for use in the diagnosis, niques.E Cosmetics are the mainstay of eyelash enhance- cure, mitigation, treatment, or prevention
    [Show full text]
  • Paraneoplastic Pemphigus: an Unusual Neoplasm Association
    erimenta xp l D E e r & m l a a t c o i l n o i Journal of Clinical & Experimental Toosi et al. J Clin Exp Dermatol Res 2011, 2:4 l g y C f R DOI: 10.4172/2155-9554.1000124 o e l ISSN: 2155-9554 s a e n a r r u c o h J Dermatology Research Case Report Open Access Paraneoplastic Pemphigus: An Unusual Neoplasm Association Parviz Toosi1, Zahra Asadi Kani2, Mehdi Qeisari2 and Nastaran Namazi3* 1Professor of dermatology, Skin research center, Shohad-e-Tajrish hospital, Shahid Beheshti university of medical science, Tehran, Iran 2Dermatopathologist, Skin research center, Shohad-e-Tajrish hospital, Shahid Beheshti university of medical science, Tehran, Iran 3Resident of dermatology, Skin research center, Shohad-e-Tajrish hospital, Shahid Beheshti university of medical science, Tehran, Iran Abstract The occurrence of paraneoplastic pemphigus (PNP) in childhood has been reported infrequently. Association with benign mesentry tumors has not been reported in these patients before. Here, we report an unusual case of PNP in a child that was concomitant with benign mesentry fibroma and responded to medical treatment only after surgical excision of tumor. Keywords: Paraneoplastic pemphigus; Neoplasm association; Here we report an unusual case of childhood paraneoplastic Benign tumor; Mesentry fibroma pemphigus in association with benign mesocolon fibroma that responded to tumor excision dramatically. Introduction Case Report PNP, described by Anhalt et al. in 1990, is an IgG-mediated disease, characterized clinically by polymorphous eruption with prominent A 12 year old girl was referred to our dermatology clinic because mucosal and acral involvement in the presence of a known or occult of painful mucosal erosions from one month ago, made her unable neoplasm.
    [Show full text]
  • Ocular Side Effects of Novel Anti-Cancer Biological Therapies
    www.nature.com/scientificreports OPEN Ocular side efects of novel anti‑cancer biological therapies Vicktoria Vishnevskia‑Dai1*, Lihi Rozner1, Raanan Berger2,3, Ziv Jaron1, Sivan Elyashiv1, Gal Markel2,3 & Ofra Zloto1 To examine the ocular side efects of selected biological anti‑cancer therapies and the ocular and systemic prognosis of patients receiving them. We retrospectively reviewed all medical records of patients who received biological anti‑cancer treatment from 1/2012 to 12/2017 and who were treated at our ocular oncology service. The following data was retrieved: primary malignancy, metastasis, type of biological therapy, ocular side efects, ophthalmic treatment, non‑ocular side efects, and ocular and systemic disease prognoses. Twenty‑two patients received biological therapies and reported ocular side efects. Eighteen patients (81.8%) had bilateral ocular side efects, including uveitis (40.9%), dry eye (22.7%), and central serous retinopathy (22.7%). One patient (4.5%) had central retinal artery occlusion (CRAO), and one patient (4.5%) had branch retinal vein occlusion (BRVO). At the end of follow‑up, 6 patients (27.27%) had resolution of the ocular disease, 13 patients (59.09%) had stable ocular disease, and 3 patients (13.64%) had progression of the ocular disease. Visual acuity improved signifcantly at the end of follow‑up compared to initial values. Eighteen patients (81.8%) were alive at study closure. Biological therapies can cause a wide range of ocular side efects ranging from dry eye symptoms to severe pathologies that may cause ocular morbidity and vision loss, such as uveitis, CRAO and BRVO. All patients receiving biological treatments should be screened by ophthalmologists before treatment, re‑screened every 4–6 months during treatment, and again at the end of treatment.
    [Show full text]
  • Case Report Follicular Lymphoma with Paraneoplastic Pemphigus As the First Symptom: a Case Report and Review of the Literature
    Int J Clin Exp Pathol 2020;13(7):1915-1923 www.ijcep.com /ISSN:1936-2625/IJCEP0112784 Case Report Follicular lymphoma with paraneoplastic pemphigus as the first symptom: a case report and review of the literature Shishou Wu1,2, Dong Gao3, Yuanfeng Zhang4, Ping Yang2, Yunjun Wang1,2, Ning Wang2, Jianfeng Xu5, Guohua Yu1,2 1Department of Clinical Medicine, Binzhou Medical University, Yantai, China; Departments of 2Pathology, 3Dermo- tology, 4Hematology, 5Respiratory Medicine, Affiliated Yantai Yuhuangding Hospital, Qingdao University, Yantai, China Received April 18, 2020; Accepted June 3, 2020; Epub July 1, 2020; Published July 15, 2020 Abstract: Paraneoplastic pemphigus (PNP) is an autoimmune bullous dermatosis associated with tumors, first de- scribed by Anhalt et al. in 1990. Reports of paraneoplastic pemphigus complicated by follicular lymphoma (FL) are rare in the medical literature. Here, we retrospectively analyze a case of PNP accompanied by FL. The patient was a 54-year-old woman who suffered from PNP associated with FL at the beginning. She had received a pathological diagnosis and was treated with R-CHOP and other drugs. Her mucosal lesions and cutaneous lesions improved, and the FL was in remission. Eleven months later, she died of BO after receiving the diagnosis of PNP. We also review most of the studies and reports about PNP accompanied by FL. We list the clinicopathologic features, therapeutic schedule, and prognosis in order to improve hematologists’ understanding and treatment of the diseases. Keywords: Follicular lymphoma, paraneoplastic pemphigus, bronchiolitis obliterans Introduction Bronchiolitis obliterans (BO) is a life-threaten- ing form of irreversible, obstructive lung dis- PNP is a rare paraneoplastic, systemic autoim- ease.
    [Show full text]
  • S2 Table. List of Syntax for 96 Diseases
    S2 Table. List of syntax for 96 diseases 'autoimmune gastritis'/exp OR 'acantholysis'/exp OR 'acantholysis' OR 'acute disseminated encephalomyelitis'/exp OR 'adem (acute disseminated encephalomyelitis)' OR 'acute disseminated encephalitis' OR 'acute disseminated encephalomyelitis' OR 'encephalitis postvaccinalis' OR 'encephalitis, post-vaccinal' OR 'encephalomyelitis, acute disseminated' OR 'post vaccinal encephalitis' OR 'post vaccination encephalitis' OR 'post-infectious encephalitis' OR 'post-infectious encephalomyelitis' OR 'postinfection encephalitis' OR 'postinfectious encephalitis' OR 'postinfectious encephalomyelitis' OR 'postvaccinal encephalitis' OR 'postvaccinal encephalopathy' OR 'postvaccination encephalitis' OR 'postvaccine encephalitis' OR 'postvaccinial encephalitis' OR 'postvaccinial encephalomyelitis' OR 'smallpox vaccination encephalitis' OR 'vaccinal encephalitis' OR 'vaccination encephalopathy' OR 'vaccination post vaccinial encephalitis' OR 'vaccinia encephalitis' OR 'addison disease'/exp OR 'addison disease' OR 'addison`s disease' OR 'addisons disease' OR 'addison biermer disease' OR 'adult onset still disease'/exp OR 'adult onset still disease' OR 'still`s disease, adult- onset' OR 'allergic glomerulonephritis'/exp OR 'allergic glomerulonephritis' OR 'glomerulonephritis, allergic' OR 'glomerulonephritis, poststreptococcal' OR 'post streptococcal glomerulonephritis' OR 'poststreptococcal glomerulonephritis' OR 'anca associated vasculitis'/exp OR 'anca associated vasculitis' OR 'anca vasculitis' OR 'anca-associated
    [Show full text]
  • Paraneoplastic Pemphigus Presenting Like Toxic Epidermal Necrolysis Huyenian Nguyen DO Lehigh Valley Health Network, [email protected]
    Lehigh Valley Health Network LVHN Scholarly Works Department of Medicine Paraneoplastic Pemphigus presenting like Toxic Epidermal Necrolysis Huyenian Nguyen DO Lehigh Valley Health Network, [email protected] Kelly L. Reed DO Lehigh Valley Health Network, [email protected] Steven Oberlender MD, PhD Lehigh Valley Health Network, [email protected] Stephen M. Purcell DO Lehigh Valley Health Network, [email protected] Follow this and additional works at: http://scholarlyworks.lvhn.org/medicine Part of the Dermatology Commons, and the Medical Sciences Commons Published In/Presented At Nguyen, H., Reed, K., Oberlender, S., & Purcell, S. (2016, March 18). Paraneoplastic Pemphigus presenting like Toxic Epidermal Necrolysis. Poster presented at Philadelphia Dermatological Society, Philadelphia, PA. Nguyen, H., Reed, K., Oberlender, S., & Purcell, S. (2016, April 26). Paraneoplastic Pemphigus presenting like Toxic Epidermal Necrolysis. Poster presented at LVHN Department of Medicine Research Day, Lehigh Valley Health Network, Allentown, PA. This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact [email protected]. Paraneoplastic Pemphigus presenting like Toxic Epidermal Necrolysis Huyenlan Nguyen, DO, Kelly Reed, DO, Steven Oberlender, MD, PhD, and Stephen M. Purcell, DO Lehigh Valley Health Network, Allentown, Pennsylvania Case Presentation: Discussion: Patient:
    [Show full text]
  • Cutaneous Manifestations of Internal Malignancies in a Tertiary Health
    736 ESPECIAL L Cutaneous manifestations of internal malignancies in a tertiary health care hospital of a developing country* Manifestações cutâneas de doenças malignas em um hospital terciário de um país em desenvolvimento Alex G. Ortega-Loayza 1 Willy Ramos 2 Ericson L. Gutierrez 3 Patricia Chavez de Paz 4 Lucia Bobbio 5 Carlos Galarza 6 Abstract: In a public hospital in Lima, Peru, 24 patients with 16 types of paraneoplastic dermatoses were iden- tified by data collection. The most frequent dermatosis was dermatomyositis (four patients). The other derma- toses were malignant acanthosis nigricans, palmoplantar keratoderma, bullous dermatoses, lymphomatoid papulosis, edematous scarring vasculitic panniculitis, Norwegian scabies, primary systemic amyloidosis, necrolytic migratory erythema, infective dermatitis, pancreatic panniculitis, generalized pruritus, Lesser-Trelat syndrome, and acquired ichthyosis. Most of these paraneoplastic dermatoses were diagnosed before (45.8%) or at the time of (38.5%) the diagnosis of the underlying malignancy. The most frequent underlying malignan- cies were lymphoma, adenocarcinomas of the upper digestive tract, and malignant neoplasms of the pancreas. The average age of the patients was 47.0 ± 16.9 years and the length of the disease since diagnosis was 13.7 months. The mortality rate was 75%. Paraneoplastic dermatoses are rare dermatologic entities that are difficult to diagnose. Surveillance is also hampered when patients do not have easy access to health care centers due to financial and geographical issues. However, when identified, they might facilitate the early diagnosis of an associated tumor and contribute to increase the surveillance of patients. Keywords: Dermatomyositis; Lymphoma; Paraneoplastic syndromes Resumo: Em um hospital público em Lima, Peru, 24 pacientes com 16 tipos de dermatoses paraneoplá- sicas foram identificados por meio de coleta de dados.
    [Show full text]